{"id":28737,"date":"2012-01-26T17:04:21","date_gmt":"2012-01-26T16:04:21","guid":{"rendered":"https:\/\/www.abcsg.org\/?page_id=28737"},"modified":"2021-02-15T08:49:39","modified_gmt":"2021-02-15T07:49:39","slug":"abcsg-publications-peer-reviewed-2006-2010","status":"publish","type":"page","link":"https:\/\/www.abcsg.org\/en\/veroeffentlichungen\/publications\/abcsg-publications-peer-reviewed-2006-2010\/","title":{"rendered":"ABCSG-Publications (peer reviewed) 2006-2010"},"content":{"rendered":"
\n
<\/span>2010<\/div>
\n

Can oral bisphosphonates really reduce the risk of breast cancer in healthy women?<\/h4>\n

Gnant M<\/p>\n

Journal of Clinical Oncology<\/p>\n

https:\/\/ascopubs.org\/doi\/full\/10.1200\/JCO.2010.29.6327<\/a><\/p>\n

\n

Neoadjuvant treatment and breast conserving surgery – a success of clinical research in breast cancer<\/h4>\n

Gnant M<\/p>\n

Wiener Medizinische Wochenschrift<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20473726<\/a><\/p>\n

\n

Results of the Zometa\u00ae Cost-Utility Model for the German Healthcare System Based on the Results of the ABCSG-12 Study<\/h4>\n

Lux M, Reichelt C, Wallwiener D, Kreienberg R, Jonat W, Gnant M, Beckmann M, Thiel F<\/p>\n

Onkologie<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20631482<\/a><\/p>\n

\n

Modulation of plasma complement by the initial dose of epirubicin\/docetaxel therapy in breast cancer and ist preditive value<\/h4>\n

Michlmayr A, Bachleitner-Hofmann T, Baumann S, Marchetti-Deschmann M, Rech-Weichselbraun I, Burghuber C, Pluschnig U, Bartsch R, Graf A, Greil R, Allmaier G, Steger G, Gnant M, Bergmann M, Oehler R<\/p>\n

British Journal of Cancer<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20877360<\/a><\/p>\n

\n

Potential Anticancer Properties of Bisphosphonates<\/h4>\n

Neville-Webbe HL, Gnant M, Coleman RE<\/p>\n

Seminars in Oncology<\/p>\n

https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0093775410000874<\/a><\/p>\n<\/div><\/div>\n

<\/span>2009<\/div>
\n

Maintaining Bone Density in Patients Undergoing Treatment for Breast Cancer: Is There and Adjuvant Benefit?<\/h4>\n

Gnant M, Dubsky P, Fitzal F, Blaha P, Schoppmann S, Steger G, Marth Ch, Samonigg H, H\u00fcttner K, Fohler H, R\u00fccklinger E, Jakesz, Greil R<\/p>\n

Clinical Breast Cancer Supplement<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19561003<\/a><\/p>\n

\n

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer<\/h4>\n

Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, P\u00f6stlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch Ch, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, R\u00fccklinger E, Greil R<\/p>\n

The New England Journal of Medicine<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19213681<\/a><\/p>\n

\n

Her2\/neu – neue Wege, neue Ziele<\/h4>\n

Mlinertisch B<\/p>\n

Wiener Medizinische Wochenschrift<\/p>\n<\/div><\/div>\n

<\/span>2008<\/div>
\n

Anemia is a significant prognostic factor in local relaspe-free survival of premenopausal primary breast cancer patients receiving adjucant Cyclophosphamide\/Methotrexate\/5-Fluorouracil chemotherapy<\/h4>\n

Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifer M, Denison U, Mlinertisch B, Steger G, Kwasny W, St\u00f6ger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, P\u00f6tter R, Gnant M<\/p>\n

Clinical Cancer Research<\/p>\n

https:\/\/clincancerres.aacrjournals.org\/content\/14\/7\/2082<\/a><\/p>\n

\n

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy<\/h4>\n

Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, K\u00e4ssmann H, Piswanger-Soelkner JC, Seifert M, Ploner F, Menzel Ch, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth Ch, Kubista E, Samonigg H, Wohlmuth P, Mittlboeck M, Jakesz R<\/p>\n

The Lancet Oncology<\/p>\n

https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(08)70204-3\/fulltext<\/a><\/p>\n

\n

Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)<\/h4>\n

Mlinertisch B, Tausch Ch, Singer Ch, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel Ch, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R<\/p>\n

Breast Cancer Research and Treatment<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18158620<\/a><\/p>\n

\n

Cyclin D1 Expression in Breast Cancer Patients Receivin Adjucant Tamoxifen-Based Therapy<\/h4>\n

Rudas M, Lehnert M, Huynh A, Jakesz R, Singer Ch, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant M, Filipits M<\/p>\n

Clinical Cancer Research<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18347178<\/a><\/p>\n

\n

The potential risk of neoadjuvant chemotherapy in breast cancer patients – results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07)<\/h4>\n

Taucher S, Steger G, Jakesz R, Tausch Ch, Wette V, Schippinger W, Kwasny W, Reiner G, Greil R, Dubsky P, Poestlberger S, Tschmelitsch J, Samonigg H, Gnant M<\/p>\n

Breast Cancer Research and Treatment<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18080748<\/a><\/p>\n<\/div><\/div>\n

<\/span>2007<\/div>
\n

Zoledronic Acid Prevents Cancer Treatment-Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group<\/h4>\n

Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel Ch, Piswanger-Soelkner JC, Galid A, Mittlboeck M, Hausmaninger H, Jakesz R<\/p>\n

Journal of Clinical Oncology<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17159195<\/a><\/p>\n

\n

Extended Adjuvant Therapy with Anastrozole Among Postmenopausal Breast Cancer Patients: Results from the Randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a<\/h4>\n

Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch Ch, Stierer M, Hofbauer F, Renner K, Dadak Ch, R\u00fccklinger E, Samonigg H<\/p>\n

Journal of the National Cancer Institute<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18073378<\/a><\/p>\n

\n

Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer<\/h4>\n

P\u00f6tter R, Gnant M, Kwasny W, Tausch Ch, Handl-Zeller L, Pakisch B, Taucher S, Hammer J, Luschin-Ebengreuth G, Schmid M, Sedlmayr F, Stierer M, Reiner G, Kapp K, Hofbauer F, Rottenfusser A, P\u00f6stlberger S, Haider K, Draxler W, Jakesz R<\/p>\n

International Journal for Radiation Oncology<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17363187<\/a><\/p>\n

\n

A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer<\/h4>\n

Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Th\u00f6dtmann R, Tschmelitsch J, Jagoditsch M, Steger G, Jakesz R, Herbst F, Hofbauer F, Rabl H, Wohlmuth P, Gnant M, Thaler J<\/p>\n

British Journal of Cancer<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17895886<\/a><\/p>\n

\n

Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14<\/h4>\n

Steger G, Galid A, Gnant M, Mlineritsch B, Lang A, Tausch Ch, Rudas M, Greil R, Wenzel C, Singer Ch, Haid An, P\u00f6stlberger S, Samonigg H, Luschin-Ebengreuth G, Kwasny W, Klug E, Kubista E, Menzel Ch, Jakesz R<\/p>\n

Journal of Clinical Oncology<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17513805<\/a><\/p>\n

\n

Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)<\/h4>\n

Mlineritsch B, Tausch Ch, Singer Ch, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel Ch, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R<\/p>\n

Breast Cancer Res Treat DOI 10.1007\/s10549-007-9843-x<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18158620<\/a><\/p>\n

\n

The potential risk of neoadjuvant chemotherapy in breast cancer patients\u2014results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07)<\/h4>\n

Taucher S, Steger G, Jakesz R, Tausch Ch, Wette V, Schippinger W, Kwasny W, Reiner G, Greil R, Dubsky P, Poestlberger S, Tschmelitsch J, Samonigg H, Gnant M<\/p>\n

Breast Cancer Res Treat DOI 10.1007\/s10549-007-9844-9<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18080748<\/a><\/p>\n

\n

Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF<\/h4>\n

Wenzel C, Bartsch R, Hussian D, Pluschnig U, Altorjai G, Zielinski Ch, Lang A, Haid A, Jakesz R, Gnant M, Steger G<\/p>\n

Breast Cancer Res Treat DOI 10.1007\/s10549-006-9397-3<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17061042<\/a><\/p>\n<\/div><\/div>\n

<\/span>2006<\/div>
\n

Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis<\/h4>\n

Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Zuna I, Greenwood M, Jakesz R<\/p>\n

The Lancet Oncology<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17138220<\/a><\/p>\n<\/div><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":28699,"menu_order":395,"comment_status":"closed","ping_status":"closed","template":"page-publikationen.php","meta":{"_acf_changed":false,"footnotes":""},"tags":[],"class_list":["post-28737","page","type-page","status-publish","hentry"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-11-12 17:33:14","action":"delete","newStatus":"draft","terms":[],"taxonomy":"translation_priority","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/28737","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/comments?post=28737"}],"version-history":[{"count":1,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/28737\/revisions"}],"predecessor-version":[{"id":28738,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/28737\/revisions\/28738"}],"up":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/28699"}],"wp:attachment":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/media?parent=28737"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/tags?post=28737"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}